
PolyPid (PYPD) Stock Forecast & Price Target
PolyPid (PYPD) Analyst Ratings
Bulls say
PolyPid is viewed favorably because D-PLEX100 has replicated strong Phase 3 efficacy, cutting incisional surgical-site infections by about 60% in SHIELD II, while the NDA is already under Priority Review with a November 28, 2026 PDUFA date and no filing issues. The Azurity partnership materially derisks commercialization by providing $30M already paid, potential additional milestones of over $290M, tiered mid-teen to mid-20s royalties, and manufacturing/supply economics, all while avoiding the cost of building a U.S. sales force. Fundamental upside is further supported by a capital-light balance sheet with runway into 2028, potential NTAP reimbursement from October 1, 2027 to improve hospital economics, and optionality from broader colorectal labeling, Europe, and the Kynatrix platform.
Bears say
PolyPid is viewed negatively because its investment case is still anchored to a single product, D-PLEX100, which remains under FDA review with a November 28, 2026 PDUFA date and still faces CRL, additional-study, or labeling risk after a failed Ph3 history. Manufacturing execution in Israel, possible FDA inspection or validation issues, and reliance on Azurity for commercialization create layered uncertainty, while hospital-by-hospital adoption, slow P&T reviews, and a potential NTAP denial could keep penetration and near-term revenue weak. Financially, the setup also looks fragile: royalties, supply revenue, and milestone timing are undisclosed, launch economics are back-end weighted, the June 2025 warrant overhang adds dilution risk, and any delay could force additional dilutive financing.
This aggregate rating is based on analysts' research of PolyPid and is not a guaranteed prediction by Public.com or investment advice.
PolyPid (PYPD) Analyst Forecast & Price Prediction
Start investing in PolyPid (PYPD)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About PolyPid (PYPD) Forecast
PolyPid (PYPD) Analyst Forecast & Price Prediction
Start investing in PolyPid (PYPD)
Order type
Buy in
Order amount
Est. shares
0 shares